Lipophilicity and disposition of 1-aryl-piperazines in the rat

References

• Arendt R. M., Greenblatt D. J., De Jong R. H., Bonin J. D., Abernethy D. R., Ehrenberg B. L., Giles H. G., Sellers E. M., Shader R. I. In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. Journal of Pharmacology and Experimental Therapeutics 1983; 227: 98–106
   PubMedGoogle Scholar
• Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences 1979; 68: 1071–1074
   PubMed Web of Science ®Google Scholar
• Breyer U. Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats. Biochemical Pharmacology 1972; 21: 1419–1429
   PubMed Web of Science ®Google Scholar
• Caccia S., Notarnicola A., Fong M. H., Benfenati E. Identification and quantitation of 1-arylpiperazines, metabolites resulting from side-chain cleavance of (4-substituted aryl-1-piperazinyl)alkyl heterocyclic derivatives in rat plasma and brain. Journal of Chromatography 1984; 203: 211–221
   Google Scholar
• Caccia S., Fong M. H., Garattini S., Zanini M. G. Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone. Journal of Pharmacy and Pharmacology 1982; 34: 605–606
   PubMed Web of Science ®Google Scholar
• Caccia S., Conti I., Notarnicola A. In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine. Journal of Pharmacy and Pharmacology 1985a; 37: 75–77
   PubMed Web of Science ®Google Scholar
• Caccia S., Fong M. H., Guiso G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 1985b; 15: 835–844
   PubMed Web of Science ®Google Scholar
• Caccia S., Fong M. H., Urso R. Ionization constants and partition coefficients of 1-arylpiperazine derivatives. Journal of Pharmacy and Pharmacology 1985c; 37: 567–570
   PubMed Web of Science ®Google Scholar
• Cervo L., Ballabio M., Caccia S., Samanin R. Blockade by trazodone of naloxone-precipitated jumping in morphine-dependent rats: correlation with brain levels of m-chlorophenylpiperazine. Journal of Pharmacy and Pharmacology 1981; 33: 813–814
   Google Scholar
• Fong M. H., Aarons L., Urso R., Caccia S. Ionization constants and lipophilicity of 1-arylpiperazines investigated by reversed-phase high-performance liquid chromatography. Journal of Chromatography 1985; 333: 191–197
   Google Scholar
• Fuller R. W., Mason N. R. Structure-activity relationships in the actions of 1-phenyl-piperazines on brain serotonin receptors. Advances in Experimental Medicine and Biology 1981; 133: 359–368
   Google Scholar
• Fuller R. W., Snoddy H. D., Mason N. R., Molloy B. B. Effect of 1-(m-trifluoromethylphenyl)-piperazine on 3H-serotonin binding to membranes from rat brain in vitro and on serotonin turnover in rat brain. in vivo. European Journal of Pharmacology 1978; 52: 11–16
   PubMed Web of Science ®Google Scholar
• Fuller R. W., Snoody H. D., Mason N. R., Owen J. E. Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 1981; 20: 155–162
   PubMed Web of Science ®Google Scholar
• Gammans R. E., Mayol R. F., LaBudde J. A., Casten G. P. Metabolic fate of 14C/15N-huspirone in man. Federation Proceedings 1982; 41: 1335
   Google Scholar
• Gibaldi M., Perrier D. Pharmacokinetics, 2nd. ed. Marcel Dekker, New York 1982
   Google Scholar
• Goldstein A., Aronow L., Kalman S. N. Principles of Drug Action. The Basis of Pharmacology, 2nd. ed. John Wiley, New York 1974
   Google Scholar
• Huff J. R., King S. W., Saari W. S., Springer J. P., Martin G. E., Williams M. Bioactive conformation of 1-arylpiperazines at central serotonin receptors. Journal of Medicinal Chemistry 1985; 28: 945–948
   Google Scholar
• Kuntzman R., Klutch A., Tsai I., Burns J. J. Physiological distribution and metabolic inactivation of chlorcyclizine and cyclizine. Journal of Pharmacology and Experimental Therapeutics 1965; 149: 29–35
   PubMed Web of Science ®Google Scholar
• Maj J., Lewandowska A. Central serotonin mimetic action of phenylpiperazines. Polish Journal of Pharmacology and Pharmacy 1980; 32: 495–504
   PubMedGoogle Scholar
• Murray T. F., McGill W., Cheney D. L. A comparison of the analgesic activities of 4,5,6,7-tetrahydroisoxazolol[5,4-c]pyridin-3-OL(THIP) and 6-chloro-2[1-piperazinyl]pyrazine (MK 212). European Journal of Pharmacology 1983; 90: 179–184
   Google Scholar
• Pettibcne D. J., Williams M. Serotonin-releasing effects of substituted piperazines. in vitro. Biochemical Pharmacology 1984; 33: 1531–1535
   Google Scholar
• Saari W. S., Halczenko W., King S. W., Huff J. R., Guare J. P., Jr, Hunt C. A., Randall W. C., Anderson P. C., Lotti V. J., Taylor D. A., Clineschmidt B. V. Pyridinylpiperazines, a new class of selective α2-adrenoceptor antagonists. Journal of Medicinal Chemistry 1983; 26: 1696–1701
   Google Scholar
• Toon S., Rowland M. Quantitative structure pharmacokinetic activity relationships with some tetracyclines. Journal of Pharmacy and Pharmacology 1979; 31(Suppl.)43P
   Google Scholar
• Toon S., Rowland M. Structure-pharmacokinetic relationships among the barbiturates in the rat. Journal of Pharmacology and Experimental Therapeutics 1983; 225: 752–762
   PubMed Web of Science ®Google Scholar
• Vetulani J., Sansone M., Bednarczyk B., Hano J. Different effects of 3-chloro-phenylpiperazine on locomotor activity and acquisition of conditioned avoidance response in different strains of mice. Naunym Schmiedeberg's Archives of Pharmacology 1982; 319: 271–274
   Google Scholar
• Weder H. J., Bickel M. H. Interactions of drugs with proteins II: Experimental methods, treatment of experimental data and thermodynamics of binding reactions of thymoleptic drugs and model dyes. Journal of Pharmaceutical Sciences 1970; 59: 1563–1569
   PubMed Web of Science ®Google Scholar